OpenAI launches GPT-Rosalind for biology

The rollout of GPT-Rosalind marks OpenAI's deepest push into the scientific field as it competes with Google and other tech giants in the AI-driven health sector.

The model is currently available in closed access to select research institutions and pharmaceutical companies.

OpenAI executives believe the tool will pave the way for major breakthroughs in treating diseases by automating data parsing and hypothesis testing.

However, the move also raises questions about the ethics and safety of using powerful LLMs in biological engineering.